A2

24. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 11.

25. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 12.

26. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 29.

27. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 33.

28. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 34.

29. A protein C or activated protein C polypeptide comprising a modified GLA domain, said modified GLA domain comprising three amino acid substitutions at positions selected from the group consisting of residues 11, 12, 29, 33 and 34.

30. The protein C or activated protein C polypeptide of claim 29, wherein said three amino acid substitutions are at residues 12, 33 and 34.

31. The protein C or activated protein C polypeptide of claim 30, wherein residue 33 is glutamic acid.

SUB B2

32. The protein C or activated protein C polypeptide of claim 30, wherein residue 34 is aspartic acid.

33. The protein C or activated protein C polypeptide of claim 30, wherein residue 33 is glutamic acid and residue 34 is aspartic acid.

A2 34. The protein C or activated protein C polypeptide of claim 29, wherein residue 11 is glutamine.

35. A pharmaceutical composition comprising said protein C or activated protein C polypeptide of any one of claims 23-34 and a pharmaceutically acceptable carrier.

36. The composition of claim 35 for use in treating thrombosis in a mammal.

37. The composition of claim 35 for use in decreasing clot formation in a mammal.

38. The composition of claim 36, wherein said composition is formulated for parenteral administration to a human patient.

39. The composition of claim 37, wherein said composition is formulated for parenteral administration to a human patient.

40. An isolated nucleic acid, said nucleic acid comprising a nucleic acid sequence encoding said protein C or activated protein C polypeptide of claim 23 or claim 29.

41. A method of producing the protein C or activated protein C polypeptide of any one of claims 23-34, said method comprising expressing an isolated nucleic acid encoding said protein C or activated protein C polypeptide in a mammalian host cell.

42. The method of claim 40, wherein said mammalian host cell is an adenovirus-transfected human kidney 293 cell.--

ADD B3